“Take 2 tablets and call me in the morning“ We’ve moved, finally, beyond assuming that an off-the-cuff statement like “take 2 and call me in the morning” is sufficient. But maybe we haven’t moved far enough to ask the important… Continue Reading
This year, you can’t swing the proverbial “dead cat” without running into a meeting on Real World Evidence. This flurry of activity portends good things in that decision-makers are placing greater importance on real world effectiveness data. Most of us… Continue Reading
It’s well-accepted that the Indian pharmaceuticals market cannot be ignored. India will be one of the top 10 sales markets by 2020, fueled by the rapid growth in its population and economy. Commensurately, India is experiencing expansion within its middle-class… Continue Reading
Maintaining high levels of patient recruitment, adherence and retention is essential for the successful completion of a clinical trial, yet it remains a significant challenge faced by researchers. Poor patient adherence and retention can adversely affect a trial by lengthening… Continue Reading
What do you think? Should PROs be included in composite endpoints along with more traditional clinical measures? Read Cardiovascular Disease and Patient-reported Outcomes – Can Composite Endpoints Work? by Caitlin Rothermel and weigh in!